Congo began vaccinating health workers with a vaccine not known to work on this virus

On 27 August, vaccination of health care workers using the Ervebo vaccine began in parts of the Democratic Republic of the Congo, including Kisangani in Tshopo province [s1]. The World Health Organization's own description of what is being deployed is unusually candid: "Although Ervebo is a safe vaccine, and effective against Ebola virus disease, it is not known whether it provides protection against the Bundibugyo virus in humans" [s1].

That sentence describes a genuine decision problem rather than a mistake, and it is worth setting out carefully.

Why there is no Bundibugyo vaccine

Bundibugyo virus disease is caused by one of the Orthoebolavirus species [s1]. The licensed Ebola vaccine was developed against a different species — the one WHO's update refers to by its former name, Zaire ebolavirus [s1]. WHO states plainly that no approved vaccines or specific treatments currently exist for Bundibugyo virus disease, and that outbreak control therefore relies on rapid case identification, isolation and care, contact tracing, safe burials and community engagement [s1].

Before this year there had been two documented Bundibugyo outbreaks, in Uganda in 2007 and in DRC in 2012, with case fatality ratios of 30% and 50% respectively [s1]. Two outbreaks in two decades is not a market, and it is not a development programme either. The current epidemic is the largest Ebola outbreak ever recorded in DRC, of any species [s1].

What the advisory group recommended

On 7 August, WHO's Technical Advisory Group on candidate vaccine prioritization released a report on possible candidate vaccines for Bundibugyo virus disease [s1]. Its members recommended that Ervebo, the only licensed Ebola vaccine, be prioritised for inclusion in a randomised clinical trial in the context of the ongoing DRC outbreak [s1].

WHO's framing of the 27 August rollout follows from that: starting a clinical trial of the vaccine alongside the wider use is "key to provide important new evidence and inform future use of the vaccine" [s1].

So there are two things happening at once — a randomised trial that can generate an answer, and broader deployment that cannot. That combination is the compromise. Restricting the vaccine to trial participants would answer the question faster and leave health workers unvaccinated in the meantime; deploying it widely without a trial would leave the question permanently unanswered, because there would be no comparison group.

The immunological basis for trying

There is a laboratory reason to think Ervebo might do something. A research letter published in the New England Journal of Medicine on 22 July examined stored blood samples from PREVAC, a large Ebola vaccine trial conducted in West Africa in adults and children, and found that both licensed Ebola vaccine regimens produce antibodies that bind Bundibugyo virus [s2]. The analysis drew on 179 samples [s2].

What that establishes is narrower than it sounds. Antibodies that bind a virus in an assay are not antibodies that neutralise it in a person, and neutralisation in a person is not protection from disease. The letter reports cross-reactive binding; it does not report efficacy, and the trial it drew on was not designed to test Bundibugyo protection.

Cross-reactive binding is a reason to run the trial. It is not a substitute for it.

What the trial has to overcome

Two features of the current situation make a vaccine trial harder than usual.

The first is the setting. WHO describes the outbreak as unfolding in a conflict-affected humanitarian context marked by insecurity, armed violence and large-scale displacement, with an estimated one million internally displaced people in Ituri province alone, and with insecurity restricting access for response teams and impeding surveillance and contact follow-up [s1].

The second is that a trial of an ineffective vaccine in health workers still consumes doses, cold chain, staff time and — most scarcely — community trust. WHO's update notes reported transmission among health care workers as one factor keeping its risk assessment for DRC at very high [s1], which is why health workers were prioritised. If the trial's answer is negative, the doses given outside it will have been given on a hope.

The treatment trial, for comparison

WHO is separately sponsoring a therapeutics trial. Known as PARTNERS, it began enrolment on 2 July, is open at three clinical management facilities in Ituri province, and has enrolled more than 250 people with confirmed disease [s1]. That trial is further along than the vaccine question and is running in the epicentre province, where 4,802 confirmed cases have been reported since the outbreak began [s1].

What to watch

The specific things that would move this from hope to evidence: publication of the vaccine trial protocol and its randomisation design; the number of health workers enrolled in the trial relative to the number vaccinated outside it; and an interim readout. WHO publishes Disease Outbreak News on this outbreak biweekly [s1], which is the most likely place for the first figures to appear.

This article describes an outbreak response and the evidence behind it. It is not medical advice.

Sources

• Ebola disease caused by Bundibugyo virus - Democratic Republic of the Congo (Disease Outbreak News, 2026-DON616), World Health Organization, 28 August 2026
• Cross-Reactive Bundibugyo Antibody Responses after Receipt of Licensed Ebola Vaccines, New England Journal of Medicine, 22 July 2026